| Funding Opportunity ID: | 330581 | | Opportunity Number: | RFA-DA-21-015 | | Opportunity Title: | Novel Approaches to Decrease Stigma of Substance Use Disorders in order to Facilitate Prevention, Treatment, and Support During Recovery (R41/R42 – Clinical Trials Optional) | | Opportunity Category: | Discretionary | | Opportunity Category Explanation: | | | Funding Instrument Type: | Grant | | Category of Funding Activity: | Education
Health | | Category Explanation: | | | CFDA Number(s): | 93.279 | | Eligible Applicants: | Small businesses | | Additional Information on Eligibility: | Other Eligible Applicants include the following: Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, may be allowed. | | Agency Code: | HHS-NIH11 | | Agency Name: | Department of Health and Human Services
National Institutes of Health | | Posted Date: | Dec 23, 2020 | | Close Date: | Feb 26, 2021 | | Last Updated Date: | Dec 23, 2020 | | Award Ceiling: | $256,580 | | Award Floor: | $0 | | Estimated Total Program Funding: | $2,000,000 | | Expected Number of Awards: | | | Description: | The purpose of this Funding Opportunity Announcement is to support research applications for commercializable products aimed at reducing stigma around substance use disorders (SUD). Phase I applications are invited to develop and evaluate feasibility of novel digital technologies, services or other interventions to reduce stigma towards SUD in clinical care, including HIV prevention and care settings, clinical training and other relevant settings, and to establish methods to measure stigma reduction. Phase II applications are invited to demonstrate efficacy in decreasing stigma towards SUD and commercialization potential of these products in clinical care, training, and/or other relevant settings, including those providing HIV prevention and care with the goal to remove barriers to SUD prevention, treatment, and support during recovery. Phase II applications focused on HIV prevention and care settings are invited to demonstrate efficacy in decreasing stigma towards SUD and improving health outcomes for people living with HIV and SUD. | | Version: | 1 |
|
